

Tea Pemovska

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8594364/publications.pdf>

Version: 2024-02-01

43
papers

1,595
citations

643344

15
h-index

563245

28
g-index

43
all docs

43
docs citations

43
times ranked

3469
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	7.7	77
2	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	1.7	7
3	Core-binding factor leukemia hijacks the T-cell-prone PU.1 antisense promoter. <i>Blood</i> , 2021, 138, 1345-1358.	0.6	12
4	Cell-surface SLC nucleoside transporters and purine levels modulate BRD4-dependent chromatin states. <i>Nature Metabolism</i> , 2021, 3, 651-664.	5.1	7
5	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. <i>Nature Communications</i> , 2021, 12, 7190.	5.8	7
6	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	0.6	1
7	Metabolic Drug Survey Highlights Cancer Cell Dependencies and Vulnerabilities. <i>Blood</i> , 2020, 136, 26-27.	0.6	0
8	Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. <i>Nature Chemical Biology</i> , 2019, 15, 232-240.	3.9	34
9	Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions. <i>Haematologica</i> , 2019, 104, 1935-1949.	1.7	93
10	8-Cladenosine activity in FLT3-ITD acute myeloid leukemia. <i>Journal of Cellular Physiology</i> , 2019, 234, 16295-16303.	2.0	12
11	Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling. <i>Leukemia</i> , 2018, 32, 774-787.	3.3	75
12	Recent advances in combinatorial drug screening and synergy scoring. <i>Current Opinion in Pharmacology</i> , 2018, 42, 102-110.	1.7	80
13	JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. <i>Blood</i> , 2017, 130, 789-802.	0.6	90
14	Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. <i>Leukemia</i> , 2017, 31, 1187-1195.	3.3	44
15	HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia. <i>Leukemia</i> , 2017, 31, 301-309.	3.3	61
16	Idelalisib sensitivity and mechanisms of disease progression in relapsed TCF3-PBX1 acute lymphoblastic leukemia. <i>Leukemia</i> , 2017, 31, 51-57.	3.3	42
17	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. <i>Oncotarget</i> , 2017, 8, 22606-22615.	0.8	13
18	Integrated ATAC-Seq and Chemosensitivity Profiling Identifies Rational Drug Combinations in Ibrutinib-Treated CLL Patients. <i>Blood</i> , 2017, 130, 800-800.	0.6	0

#	ARTICLE	IF	CITATIONS
19	8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth and Synergizes with the BCL-2 Inhibitor Venetoclax (ABT-199). <i>Blood</i> , 2016, 128, 2758-2758.	0.6	0
20	From drug response profiling to target addiction scoring in cancer cell models. <i>DMM Disease Models and Mechanisms</i> , 2015, 8, 1255-1264.	1.2	13
21	Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing. <i>Blood Cancer Journal</i> , 2015, 5, e309-e309.	2.8	19
22	Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. <i>Nature</i> , 2015, 519, 102-105.	13.7	207
23	Stromal-Derived Factors Modulate Ex Vivo Drug Responses of Primary Acute Myeloid Leukemia Cells. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, S8-S9.	0.2	0
24	8-Chloro-Adenosine Inhibits Molecular Poor-Risk Acute Myeloid Leukemia (AML) and Leukemic Stem Cells (LSC) Growth Via Novel RNA- and ATP-Directed Mechanisms: A Novel Therapeutic Approach for AML. <i>Blood</i> , 2015, 126, 792-792.	0.6	2
25	BCL2-Inhibitors Target a Major Group of Newly-Diagnosed and Relapsed/Refractory Acute Myeloid Leukemia Ex Vivo. <i>Blood</i> , 2015, 126, 2462-2462.	0.6	0
26	JAK1/2 and BCL2 Inhibitors Synergize to Counter-Act Bone Marrow Stromal Cell-Induced Protection of AML. <i>Blood</i> , 2015, 126, 867-867.	0.6	0
27	A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland. <i>Synergy</i> , 2014, 1, 78.	1.1	4
28	Novel activating STAT5B mutations as putative drivers of T-cell acute lymphoblastic leukemia. <i>Leukemia</i> , 2014, 28, 1738-1742.	3.3	90
29	Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. <i>Scientific Reports</i> , 2014, 4, 5193.	1.6	243
30	Discovery of Novel Drug Sensitivities in T-Prolymphocytic Leukemia (T-PLL) By High-Throughput Ex Vivo Drug Testing and Genetic Profiling. <i>Blood</i> , 2014, 124, 917-917.	0.6	0
31	Stroma-Derived Factors Significantly Impact the Drug Response Profiles of Patient-Derived Primary AML Cells: Implications for Drug Sensitivity Testing. <i>Blood</i> , 2014, 124, 3505-3505.	0.6	0
32	Analysis of Clonal Evolution in Chemorefractory Acute Myeloid Leukemia from Diagnosis to Relapse. <i>Blood</i> , 2014, 124, 1022-1022.	0.6	0
33	AML Specific Targeted Drugs Identified By Drug Sensitivity and Resistance Testing: Comparison of Ex Vivo Patient Cells with in Vitro Cell Lines. <i>Blood</i> , 2014, 124, 2163-2163.	0.6	1
34	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. <i>Blood</i> , 2014, 124, 3139-3139.	0.6	0
35	Individualized Systems Medicine Strategy to Tailor Treatments for Patients with Chemorefractory Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2013, 3, 1416-1429.	7.7	334
36	Novel Activating STAT5B Mutations As Drivers Of T-ALL. <i>Blood</i> , 2013, 122, 3863-3863.	0.6	5

#	ARTICLE	IF	CITATIONS
37	Stromal Cell Supported High-Throughput Drug Testing Of Primary Leukemia Cells For Comprehensive Assessment Of Sensitivity To Novel Therapies. <i>Blood</i> , 2013, 122, 1668-1668.	0.6	0
38	Primary T-Prolymphocytic Leukemia (T-PLL) Cells Are Sensitive To BCL-2 and HDAC Inhibitors: Results From High-Throughput Ex Vivo Drug Testing. <i>Blood</i> , 2013, 122, 3828-3828.	0.6	0
39	Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling. <i>Blood</i> , 2013, 122, 482-482.	0.6	0
40	High-Throughput Drug Sensitivity and Resistance Testing (DSRT) Platform Reveals Novel Candidate Drugs For Advanced Phase BCR-ABL1-Positive Leukemia. <i>Blood</i> , 2013, 122, 2719-2719.	0.6	0
41	High-Throughput Ex Vivo Drug Sensitivity and Resistance Testing (DSRT) Integrated with Deep Genomic and Molecular Profiling Reveal New Therapy Options with Targeted Drugs in Subgroups of Relapsed Chemorefractory AML. <i>Blood</i> , 2012, 120, 288-288.	0.6	1
42	Development of metastatic HER2 ⁺ breast cancer is independent of the adaptive immune system. <i>Journal of Pathology</i> , 2011, 224, 56-66.	2.1	21
43	Development of a Cancer Pharmacopeia-Wide Ex-Vivo Drug Sensitivity and Resistance Testing (DSRT) Platform: Identification of MEK and mTOR As Patient-Specific Molecular Drivers of Adult AML and Potent Therapeutic Combinations with Dasatinib. <i>Blood</i> , 2011, 118, 2487-2487.	0.6	0